DaVita Clinical Research Announces New Biorepository Services
DaVita Clinical Research
announced its Biorepository Services. These services offer the pharmaceutical industry collaborative research opportunities that combine access to high-quality samples combined with well-characterized patient data annotation.
DCR’s distinctive Biorepository Services support industry trends toward personalized medicine, empowered drug discovery and productive drug development for biotechnology and pharmaceutical sponsors, as well as platform technology companies. This approach aims to provide meaningful advances toward the future of more effective drug discovery and development.
“We are excited to begin this new chapter and believe the biorepository we are creating will set a new standard in the industry and add value to the drug discovery efforts of our partners,” stated DCR President Chris Rucker . “We believe that the unique characteristics of our offering will position us to meet a need in the discovery community that is currently not being satisfied by the existing biorepositories.”
DCR’s biorepository provides customized sample sets from patient populations collected nationally. These samples are collected under an IRB-approved protocol with the consent of patients. The samples contain high RNA and DNA yields and are suitable for genomic analysis. In addition, DCR collects samples under the same rigorous conditions that allow proteomic and metabolomic testing.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
